Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The oncofetal protein SALL4 is crucial for cancer cell survival.
• Targeting SALL4 is currently limited to patients whose tumors express this protein.

Purpose of the Study:

• To engineer a partial dependency on SALL4 in cancer cells to broaden SALL4-centered therapeutic strategies.
• To investigate the efficacy of sequential treatment with 5-aza-2'-deoxycytidine (DAC) and entinostat in SALL4-dependent cancer cells.

Main Methods:

• Exogenous expression of SALL4 to induce partial dependency in SALL4-negative cancer cells.
• Treatment with DAC to transiently upregulate SALL4.
• Sequential treatment with DAC and entinostat, assessing SALL4 dependency and miRNA-205 involvement.
• In vitro and in vivo validation of the therapeutic approach.

Main Results:

• SALL4-negative cancer cells successfully developed a partial dependency on exogenous SALL4.
• DAC pretreatment sensitized these cells to entinostat by modulating SALL4 expression via miRNA-205.
• SALL4 was essential for the combined efficacy of the DAC-entinostat sequential treatment.
• The engineered dependency and sequential therapy demonstrated effectiveness both in cell cultures and in vivo.

Conclusions:

• This study presents a novel framework for expanding targeted therapies by inducing transient target expression and engineering cancer cell dependency.
• The findings offer a potential therapeutic strategy for patients lacking suitable molecular targets by creating a SALL4-mediated vulnerability.